Kiniksa Announces U.S. FDA Acceptance of sBLA and Priority Review for Rilonacept in Recurrent Pericarditis

    NEXT STORY
    Generex and NuGenerex Immuno-Oncology Ii-Key-SARS-CoV-2 Vaccine Partner Bintai Kinden Executes its Exclusive Distribution & Licensing Option for Australia and New Zealand
    PREV STORY
    Cytokinetics Regains Rights to Develop and Commercialize Omecamtiv Mecarbil and AMG 594 From Amgen
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma

    The three-year relapse-free survival (RFS) rate for patients treated with the combination was 58%, ...

    author_avatar
    NASDAQ Market News

    Sorrento Therapeutics CEO Dr Ji to Present at LEERINK Partners 7th Global Healthcare Conference on 02/15/18

    SAN DIEGO, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ("Sorrento"), announced ...

    author_avatar
    NASDAQ Market News

    Aduro Biotech Receives $22.4 Million in Clinical Development Milestone Payments From Janssen

    BERKELEY, Calif., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced ...

    author_avatar
    NASDAQ Market News